XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide.
The last earnings update was 22 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
XORTX Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
XORTX Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as XORTX Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare XORTX Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare XORTX Therapeutics's earnings growth to the Canada market average as no estimate data is available.
Unable to compare XORTX Therapeutics's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if XORTX Therapeutics is high growth as no earnings estimate data is available.
Unable to determine if XORTX Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
XORTX Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
XORTX Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
XORTX Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
XORTX Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
XORTX Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 17.2x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Allen W. Davidoff, Ph.D. is founder and has been its Chief Executive Officer and President at XORTX Pharma Corp. , since January 9, 2018. Mr. Davidoff served as the Chief Scientific Officer of Stem Cell Therapeutics Corp. from December 31, 2010 to March 2012 and also served as its Vice President of Product Development from December 2004 to December 31, 2010. From September 2003 to December 2004, Mr. Davidoff served as Senior Clinical Scientist of Cardiome Pharma Corp. From September 2002 to March 2003, Dr. Davidoff served as Biotechnology Analyst for Lightyear Capital Inc., an investment dealer. His overall experience includes over 10 years of drug development experience with broad clinical and regulatory leadership experience. His senior management experience in pharmaceutical R&D includes two investigational new drug (IND) applications or supplemental IND's, two phase I studies (four multi-country), seven phase II studies and one NDA. He serves as a Director of XORTX Pharma Corp. He serves as a Director of Patient Stem Cell Resource Inc. Dr. Davidoff served as Director of Neurogenesis.
Insufficient data for Allen to compare compensation growth.
Allen's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the XORTX Therapeutics management team is less than 2 years, this suggests a new team.
Chief Financial Officer
Executive Consultant of Clinical & Regulatory Affairs
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the XORTX Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Paul Van Damme
Member of Scientific Advisory Board
Henk ter Keurs
Member of Scientific Advisory Board
Member of Clinical Advisory Board
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by XORTX Therapeutics individual insiders in the past 3 months, but not in substantial volumes.
Did You Manage To Avoid XORTX Therapeutics's (CNSX:XRX) 15% Share Price Drop?
It seems likely some shareholders believe that XORTX Therapeutics will significantly advance the business plan before too long. … But with the share price diving 15% in the last year, it's probably fair to say that some shareholders no longer believe the company will succeed. … A Different Perspective While XORTX Therapeutics shareholders are down 15% for the year, the market itself is up 1.1%.
What Kind Of Shareholders Own XORTX Therapeutics Inc. (CNSX:XRX)?
Generally speaking, as a company grows, institutions will increase their ownership. … XORTX Therapeutics is a smaller company with a market capitalization of CA$11m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that.
Breaking Down XORTX Therapeutics Inc's (CNSX:XRX) Ownership Structure
I am going to take a deep dive into XORTX Therapeutics Inc’s (CNSX:XRX) most recent ownership structure, not a frequent subject of discussion among individual investors. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … CNSX:XRX Ownership Summary August 22nd 18
XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. It has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. The company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. In addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. The company has strategic alliance with Teijin Pharma Limited to develop TMX-049, a xanthine oxidoreductase. XORTX Therapeutics Inc. is headquartered in Calgary, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.